Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Reltecimod (AB-103) TFA is an antagonist of the T-cell-specific surface glycoprotein CD28 (TP44), demonstrating efficacy against various bacterial infections, including their exotoxins and endotoxins, as well as ionizing radiation. By modulating the inflammatory response through attenuation of the key CD28/B7-2 co-stimulatory pathway without full inhibition, Reltecimod TFA is utilized in researching necrotizing soft-tissue infections (NSTIs) [1].
Description | Reltecimod (AB-103) TFA is an antagonist of the T-cell-specific surface glycoprotein CD28 (TP44), demonstrating efficacy against various bacterial infections, including their exotoxins and endotoxins, as well as ionizing radiation. By modulating the inflammatory response through attenuation of the key CD28/B7-2 co-stimulatory pathway without full inhibition, Reltecimod TFA is utilized in researching necrotizing soft-tissue infections (NSTIs) [1]. |
In vivo | Reltecimod, administered intravenously at dosages ranging from 1.25 to 5 mg/kg, has been shown to enhance survival rates in mice infected with various bacteria [1]. |
Synonyms | AB-103 TFA |
Molecular Weight | 1037.19 (free base) |
Formula | C46H72N10O15S.xC2HF3O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Reltecimod TFA AB-103 TFA inhibitor inhibit